DOI QR코드

DOI QR Code

Inhibitory Effect of a Phosphatidyl Ethanolamine Derivative on LPS-Induced Sepsis

  • Lee, Chunghyun (Department of Biology, School of Bioscience and Biotechnology, Chungnam National University) ;
  • An, Hyun-Jung (Department of Biology, School of Bioscience and Biotechnology, Chungnam National University) ;
  • Kim, Jung-In (Department of Chemistry, Korea Advanced Institute of Science and Technology) ;
  • Lee, Hayyoung (Department of Biology, School of Bioscience and Biotechnology, Chungnam National University) ;
  • Paik, Sang-Gi (Department of Biology, School of Bioscience and Biotechnology, Chungnam National University)
  • Received : 2009.01.13
  • Accepted : 2009.01.28
  • Published : 2009.02.28

Abstract

Sepsis is the leading cause of death in critically ill patients. Today, around 60% of all cases of sepsis are caused by Gram-negative bacteria. The cell wall component lipopolysaccharide (LPS) is the main initiator of the cascade of cellular reactions in Gram-negative infections. The core receptors for LPS are toll-like receptor 4 (TLR4), MD-2 and CD14. Attempts have been made to antagonize the toxic effect of endotoxin using monoclonal antibodies against CD14 and synthetic lipopolysaccharides but there is as yet no effective treatment for septic syndrome. Here, we describe an inhibitory effect of a phosphatidylethanolamine derivative, PE-DTPA (phosphatidylethanolamine diethylenetriaminepentaacetate) on LPS recognition. PE-DTPA bound strongly to CD14 ($K_d$, $9.52{\times}10^{-8}M$). It dose dependently inhibited LPS-mediated activation of human myeloid cells, mouse macrophage cells and human whole blood as measured by the production of tumor necrosis factor-${\alpha}$ (TNF-${\alpha}$) and nitric oxide, whereas other phospho-lipids including phosphatidylserine and phosphatidylethanolamine had little effect. PE-DTPA also inhibited transcription dependent on $NF-{\kappa}B$ activation when it was added together with LPS, and it rescued LPS-primed mice from septic death. These results suggest that PE-DTPA is a potent antagonist of LPS, and that it acts by competing for binding to CD14.

Keywords

Acknowledgement

Supported by : Korea Science and Engineering Foundation

References

  1. Angus, D.C., and Wax, R.S. (2001). Epidemiology of sepsis: an update. Crit. Care Med. 29, S109-116 https://doi.org/10.1097/00003246-200107001-00035
  2. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M.R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 https://doi.org/10.1097/00003246-200107000-00002
  3. Bas, S., Gauthier, B.R., Spenato, U., Stingelin, S., and Gabay, C. (2004). CD14 is an acute-phase protein. J. Immunol. 172, 4470-4479 https://doi.org/10.4049/jimmunol.172.7.4470
  4. Bochkov, V.N., Kadl, A., Huber, J., Gruber, F., Binder, B.R., and Leitinger, N. (2002). Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419, 77-81 https://doi.org/10.1038/nature01023
  5. Dziarski, R., Tapping, R.I., and Tobias, P.S. (1998). Binding of bacterial peptidoglycan to CD14. J. Biol. Chem. 273, 8680-8690 https://doi.org/10.1074/jbc.273.15.8680
  6. Gregory, C.D., and Devitt, A. (1999). CD14 and apoptosis. Apoptosis 4, 11-20 https://doi.org/10.1023/A:1009673914340
  7. Haziot, A., Ferrero, E., Kontgen, F., Hijiya, N., Yamamoto, S., Silver, J., Stewart, C.L., and Goyert, S.M. (1996). Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 4, 407-414 https://doi.org/10.1016/S1074-7613(00)80254-X
  8. Kim, J.I., Lee, C.J., Jin, M.S., Lee, C.H., Paik, S.G., Lee, H., and Lee, J.O. (2005). Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J. Biol. Chem. 280, 11347-11351 https://doi.org/10.1074/jbc.M414607200
  9. Mullarkey, M., Rose, J.R., Bristol, J., Kawata, T., Kimura, A., Kobayashi, S., Przetak, M., Chow, J., Gusovsky, F., Christ, W.J., et al. (2003). Inhibition of endotoxin response by e5564, a novel Tolllike receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304, 1093-1102 https://doi.org/10.1124/jpet.102.044487
  10. Raetz, C.R., and Whitfield, C. (2002). Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635-700 https://doi.org/10.1146/annurev.biochem.71.110601.135414
  11. Rossignol, D.P., and Lynn, M. (2005). TLR4 antagonists for endotoxemia and beyond. Curr. Opin. Investig. Drugs 6, 496-502
  12. Schimke, J., Mathison, J., Morgiewicz, J., and Ulevitch, R.J. (1998). Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. USA 95, 13875-13880 https://doi.org/10.1073/pnas.95.23.13875
  13. Spyvee, M.R., Zhang, H., Hawkins, L.D., and Chow, J.C. (2005). Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids. Bioorg. Med. Chem. Lett. 15, 5494-5498 https://doi.org/10.1016/j.bmcl.2005.08.080
  14. Tasaka, S., Ishizaka, A., Yamada, W., Shimizu, M., Koh, H., Hasegawa, N., Adachi, Y., and Yamaguchi, K. (2003). Effect of CD14 blockade on endotoxin-induced acute lung injury in mice. Am. J. Respir. Cell Mol. Biol. 29, 252-258 https://doi.org/10.1165/rcmb.2002-0132OC
  15. Tobias, P.S., Soldau, K., Iovine, N.M., Elsbach, P., and Weiss, J. (1997). Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. J. Biol. Chem. 272, 18682-18685 https://doi.org/10.1074/jbc.272.30.18682
  16. Triantafilou, M., and Triantafilou, K. (2002). Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 23, 301-304 https://doi.org/10.1016/S1471-4906(02)02233-0
  17. Ulevitch, R.J., and Tobias, P.S. (1995). Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13, 437-457 https://doi.org/10.1146/annurev.iy.13.040195.002253
  18. Wang, P.Y., Kitchens, R.L., and Munford, R.S. (1998). Phosphatidylinositides bind to plasma membrane CD14 and can prevent monocyte activation by bacterial lipopolysaccharide. J. Biol. Chem. 273, 24309-24313 https://doi.org/10.1074/jbc.273.38.24309
  19. Wright, S.D., Ramos, R.A., Tobias, P.S., Ulevitch, R.J., and Mathison, J.C. (1990). CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249, 1431-1433 https://doi.org/10.1126/science.1698311

Cited by

  1. Myelin-phagocytosing macrophages modulate autoreactive T cell proliferation vol.8, pp.None, 2009, https://doi.org/10.1186/1742-2094-8-85
  2. UVliPiD: A UVPD-Based Hierarchical Approach for De Novo Characterization of Lipid A Structures vol.88, pp.3, 2009, https://doi.org/10.1021/acs.analchem.5b04098
  3. TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis vol.5, pp.4, 2017, https://doi.org/10.3390/vaccines5040034
  4. Towards mapping electrostatic interactions between Kdo2-lipid A and cationic antimicrobial peptides via ultraviolet photodissociation mass spectrometry vol.143, pp.15, 2009, https://doi.org/10.1039/c8an00652k
  5. Umbilical Cord Blood Mesenchymal Stem Cells Enhance Lipopolysaccharide-Induced IL-10 and IL-37 Production in THP-1 Cells vol.42, pp.3, 2009, https://doi.org/10.1007/s10753-019-00960-z
  6. Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury vol.62, pp.11, 2019, https://doi.org/10.1021/acs.jmedchem.9b00316
  7. Rapamycin Inhibited Pyroptosis and Reduced the Release of IL-1 β and IL-18 in the Septic Response vol.2020, pp.None, 2009, https://doi.org/10.1155/2020/5960375